Drug profile · INN
cobimetinib
COTELLIC
cobimetinib (COTELLIC) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Associated with Hoffmann-La Roche.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01XE38
Patents linked 1
Pipeline programs 7
News articles 0
Drug details — cobimetinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 1
- Programs
- 7
- Data quality
- 0.83
Quick answer
cobimetinib (COTELLIC) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Associated with Hoffmann-La Roche.
Key facts
INN cobimetinib
Brand COTELLIC
Mechanism Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Target Dual specificity mitogen-activated protein kinase kinase 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XE38
Originator Hoffmann-La Roche
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is cobimetinib?
cobimetinib (COTELLIC) is a dual specificity mitogen-activated protein kinase kinase 2 inhibitor. Associated with Hoffmann-La Roche.
What is the brand name for cobimetinib?
COTELLIC is a marketed brand name for cobimetinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.